Blood vessel side effects from immune cancer drugs
Part of Heart & circulation, Immune system & allergy clinical trials.
This study looks at how immune checkpoint inhibitors—medicines that help your body fight cancer—might affect your blood vessels and circulation. By joining, you'll help doctors understand and better manage these potential side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Currently receiving or about to start one of these immune checkpoint inhibitor drugs: nivolumab, pembrolizumab, atezolizumab, ipilimumab, cemiplimab, or similar medications
- Age 18 or older
- Able to get around with minimal assistance (WHO performance status 0–2, meaning you can manage daily activities)
- Have not received these immune drugs before
- Have not had chemotherapy or other cancer-fighting drugs in the past 4 weeks
- Live in France and have health insurance coverage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
This trial looks at a faster heart and blood-vessel assessment for people who are taking immune cancer drugs and have been referred because they might be having a heart-related side effect. It may help by speeding up evaluation and treatment decisions when symptoms raise concern.
This trial studies whether immunotherapy drugs (called immune checkpoint inhibitors) affect the small blood vessels of the heart. If you have breast cancer or lung cancer and are starting a specific treatment plan, you may be asked to have a special heart scan before and during therapy.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
This study looks at how certain cancer drugs (called immune checkpoint inhibitors) interact with other medicines in the body. It aims to help doctors understand how to safely combine these treatments.
Hear when a new Vascular Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.